$CJMB News

Callan JMB Expands And Extends A Public Sector Infrastructure Agreement Worth ~$175K Per Month Over The Next Six Months

Callan Jmb Q1 EPS $(0.59) Down From $(0.32) YoY, Sales $1.106M Down From $1.449M YoY

Callan JMB Launches Atlas Complex, A Planned 150 Acre Campus In Alabama For Pharmaceutical Onshoring, Medical Logistics And Domestic Supply Chain Expansion

Callan Jmb Q4 EPS $(0.56), Sales $1.161M

Callan JMB Agrees With Attune Biotech To Support Its IND Clinical Trials For Treatment Of Post-Acute Sequelae Of SARS-CoV-2 Infection

Callan JMB Inc. (CJMB) Presents at IAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 Transcript

Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune for Approximately $50 to $75 Million in Total Revenue

Dow Jumps 200 Points; Goldman Sachs Earnings Top Views

Callan JMB–Attune Teaming Agreement Targets $50M-$75M In Combined Revenue, With $25M-$45M Potential Upside for Callan JMB Over The Next 5 Years

Callan JMB–Attune Teaming Agreement Targets $50M-$75M In Combined Revenue, With $25M-$45M Potential Upside for Callan JMB Over The Next 5 Years

Callan JMB shares are trading higher after the company announced it has signed a strategic teaming agreement with Biostax Corp d/b/a Attune Biotech to provide comprehensive federal oversight services.

Callan JMB Signs Strategic Teaming Agreement With Attune Biotech To Provide Comprehensive Federal Oversight Services

Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility

Callan JMB Unveils Strategic Shift Toward Cold Chain Logistics For The $100B GLP-1 Drug Market With Texas cGMP Facility Upgrade Underway

Founder of Callan JMB Picks Up 1.3% More Stock

Callan JMB Appoints Christopher Shields As Interim CFO And Treasurer

Callan JMB Announces Third Quarter 2025 Financial Results and Provides Business Update

Callan Jmb Q3 EPS $(0.61) Down From $(0.27) YoY, Sales $1.447M Up From $1.435M YoY

Callan JMB Enters Agreement to Install Oral Drug Delivery Equipment in Texas Facility

Callan JMB Enters Preliminary Agreement To Install Manufacturing Equipment In Callan JMB's cGMP Facility In Texas